Molecule Information

General Information of the Molecule (ID: Mol01312)

• Name: Papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) ,Homo sapiens
• Synonyms: PTCSC3
• Molecule Type: LncRNA
• Gene ID: 100886964
• Location: chr14:36136108-36176468[-]
• Ensembl ID: ENSG00000259104
• HGNC ID: HGNC:43959

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Doxorubicin

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Anaplastic thyroid carcinoma [1]

• Sensitive Disease: Anaplastic thyroid carcinoma [ICD-11: 2D10.3]
• Sensitive Drug: Doxorubicin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell viability; Inhibition; hsa05200
• Cell Pathway Regulation: STAT3/INO80 signaling pathway; Inhibition; hsa04066
• In Vitro Model: FTC-133 cells; Thyroid; Homo sapiens (Human); CVCL_1219
• In Vitro Model: 8505C cells; Thyroid; Homo sapiens (Human); CVCL_1054
• In Vitro Model: FTC 238 cells; Thyroid; Homo sapiens (Human); CVCL_2447
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: LncRNA PTCSC3 inhibits INO80 expression by negatively regulating STAT3, and thereby attenuating drug resistance of ATC to chemotherapy drug doxorubicin.

Unusual Activation of Pro-survival Pathway (UAPP)

Disease Class: Anaplastic thyroid cancer [1]

• Sensitive Disease: Anaplastic thyroid cancer [ICD-11: 2D10.2]
• Sensitive Drug: Doxorubicin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: STAT3/INO80 pathway; Regulation; hsa04550
• In Vitro Model: 8505C cells; Thyroid; Homo sapiens (Human); CVCL_1054
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: LncRNA PTCSC3 was low-expressed in ATC tissues and cells. Over-expressed PTCSC3 inhibited the drug resistance of ATC to doxorubicin. LncRNA PTCSC3 inhibits INO80 expression by negatively regulating STAT3, and thereby attenuating drug resistance of ATC to chemotherapy drug doxorubicin, providing novel strategies for improving efficiency of chemotherapy for ATC treatment.

Disease- and Tissue-specific Abundances of This Molecule

ICD Disease Classification 02

Thyroid cancer [ICD-11: 2D10]

Differential expression of molecule in resistant diseases

• The Studied Tissue: Thyroid
• The Specified Disease: Thyroid carcinoma
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 1.04E-29; Fold-change: 8.90E-02

References

• Ref 1: LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 2018 Jul 3;19(7):590-597. doi: 10.1080/15384047.2018.1449610. Epub 2018 May 3.